Arden forecast
This article was originally published in The Rose Sheet
Executive Summary
Elizabeth Arden predicts Q1 sales decline due to impact of Severe Acute Respiratory Syndrome, which adversely effected firm's sales in travel retail and certain international markets, fragrance distributor announces May 19. Sales projected in $133 mil.-$135 mil. range in the period compared to $140.3 mil. a year ago. Arden also expects to report net loss of $.92-$.94 per share, firm adds. Initial guidance for the year assumed some degree of caution due to the challenging retail environment, Arden says, noting it still expects to achieve net sales guidance of 5%-7% and EPS growth of 20%-25% for the full fiscal year. However, "if the SARS epidemic and the softness experienced with U.S. retailers continue to create an adverse retail environment for the remainder of the year," results likely will be negatively impacted, Arden cautions...
You may also be interested in...
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.